These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7914055)

  • 1. Antideficit properties of neuroleptics.
    Colonna L
    Acta Psychiatr Scand Suppl; 1994; 380():77-82. PubMed ID: 7914055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Profile of the action of neuroleptics in deficit schizophrenia].
    Vanelle JM
    Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug treatment of schizophrenia and delusional disorder in late life.
    Howard R
    Int Psychogeriatr; 1996; 8(4):597-608. PubMed ID: 9147173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician observations and perceptions of positive and negative symptoms of schizophrenia: a multinational, cross-sectional survey.
    Lecrubier Y; Perry R; Milligan G; Leeuwenkamp O; Morlock R
    Eur Psychiatry; 2007 Sep; 22(6):371-9. PubMed ID: 17521890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of untreated psychosis and time to treatment response for delusions and hallucinations.
    Gunduz-Bruce H; McMeniman M; Robinson DG; Woerner MG; Kane JM; Schooler NR; Lieberman JA
    Am J Psychiatry; 2005 Oct; 162(10):1966-9. PubMed ID: 16199847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia in 2 patients treated with ziprasidone.
    Ananth J; Burgoyne KS; Niz D; Smith M
    J Psychiatry Neurosci; 2004 Nov; 29(6):467-9. PubMed ID: 15644988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antipsychotics in schizophrenia: the French experience.
    Vanelle JM; Olié JP; Lévy-Soussan P
    Acta Psychiatr Scand Suppl; 1994; 380():59-63. PubMed ID: 7914051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenic and paranoid disorders in the aged.
    Varner RV; Gaitz CM
    Psychiatr Clin North Am; 1982 Apr; 5(1):107-18. PubMed ID: 6124954
    [No Abstract]   [Full Text] [Related]  

  • 9. First person account: living with the delusions and effects of schizophrenia.
    Weiner SK
    Schizophr Bull; 2003; 29(4):877-9. PubMed ID: 14989422
    [No Abstract]   [Full Text] [Related]  

  • 10. ICI 204,636: a new atypical antipsychotic drug.
    Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
    Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical classification of neuroleptics. Critical study and current prospects].
    Kapsambelis V; Gekiere C; Ginestet D
    Encephale; 1990; 16(2):63-70. PubMed ID: 1972056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():28-34. PubMed ID: 9766617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment on "tardive dyskinesia circa 2006".
    Rosenheck RA
    Am J Psychiatry; 2007 Jan; 164(1):170; author reply 170. PubMed ID: 17202564
    [No Abstract]   [Full Text] [Related]  

  • 14. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Schizophrenic deficit syndrome and neurologic tolerance].
    Verdoux H; Bourgeois M
    Encephale; 1996 Jun; 22 Spec No 2():45-7. PubMed ID: 8767042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms].
    Petit M; Langlois S
    Encephale; 1996 Jun; 22 Spec No 2():13-8. PubMed ID: 8767036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacologic approach to negative symptoms in schizophrenia].
    Jalenques I
    Encephale; 1995 Jun; 21 Spec No 3():35-40. PubMed ID: 7628340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs.
    Lindström LH
    Acta Psychiatr Scand Suppl; 1994; 380():74-6. PubMed ID: 7914054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.